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Health care
invest in its own capacity to study the organisation
financing of health care has been recognised by 
health and medical research conducted over the p
and by expert bservers and commentators.3 As 
Health and Medical Research Council (NHMRC) g
major initiative in research that aims to provide an 
for policy and practice reform,4 it is worth consiMJA • Volume 188 NumbABSTRACT
• With new funding for the National Health and Medical 
Research Council (NHMRC) to provide an evidence base for 
policy and practice reform, it is timely to revisit Australia’s 
recent experiences with health services research and policy 
development.
• We provide a broad review of the contribution of Australian 
health services research to the development of health policy 
over the past 20 years.
• We conclude that three preconditions are necessary to 
influence policy:
? political will;
? sustained funding to encourage methodological rigour 
and build decisionmakers’ confidence; and
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Plans of this nature are being drawn up largely uninformed by
evidence. The Grant report on health and medical research,1
released in 2004, yet again pointed to the underdevelopment of





ears up for a
evidence base
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Australian health services research has had an impact, and the
conditions which facilitated this.
While some major policy issues have received little research
attention, there are several examples where health services
research has made a substantial contribution. We have identified
casemix classification, coordinated care trials, development of
cost-effectiveness requirements for the Pharmaceutical Benefits
Scheme (PBS) and the health workforce as areas from which we
might draw lessons about what does and does not work in
promoting health services research capacity and activity.
Casemix
Casemix classification5 emerged in the 1980s as a measurement
tool that could explain variations in hospital lengths of stay and
costs. Its early development, in Australia and other countries, was
initiated by academic researchers, with early Australian research
followed by growing interest,6 as shown by publications, presence
in conference programs and research funding. The research was
given great impetus by national leadership and coordination,7 and
by the provision of substantial and sustained funding which was
initiated in the 1988–89 Medicare Agreement.8 Australian
researchers developed a specifically Australian casemix classifica-
tion — Australian Refined Diagnosis Related Groups (AR-DRGs)
— which has been adopted in many other countries, including
New Zealand, Ireland and Germany. Thus, funding was provided
to consolidate and extend work already underway (rather than for
another new idea), building on an environment which was ready
for implementation of this approach to hospital funding. The
research ultimately had a major impact on health services organisa-
tion and delivery through implementation of new funding arrange-
ments, first in Victoria in 1993, and subsequently in most other
states.
The coordinated care trials
The coordinated care trials were established in the mid 1990s.
There had been numerous commentaries about the inefficiencies
engendered by the split in federal–state responsibilities for health
care.9 The coordinated care trials were developed to test whether
pooling funds from federal and state sources into a common
budget would offer better service delivery, improved health out-
comes and greater efficiency. They were designed to meet local
needs, rather than the demands of research rigour. A commitment
to evaluation was made from the outset, both at the local project
level and as a national program, but the trial design preceded the
evaluation design. Results were equivocal, in terms of health
outcomes, costs and financial viability;10 consequently, there was
little direct impact on policy. Many factors are considered to have
contributed to the limited achievement of the desired objectives of
funds pooling, including the short time frame over which trials
were run, insufficient preparatory work in developing budgets, the
weakness of incentives as budget holding was notional, and lack of
experience of case coordinators. This was a major health services
research effort with national leadership and funding,11 similar to
casemix classification. It did bring together a nationwide network
of researchers and evaluators, but with relatively short time frames
for design, implementation and evaluation. Unlike casemix classi-
fication, this program did not draw on an existing body of work
developed by Australian researchers. Rather, the research effort
was initiated by the policy response, but the research was limited
to measuring trial outcomes and processes. In contrast, the RAND
Health Insurance Experiment in the United States not only
measured the outcomes of different insurance packages, it also
included a major investment in the development of methods,12
such as the development of the SF-36 questionnaire13 to measure
relevant health outcomes. Methodological advances, as well as the
results of the experiment per se, have had a major impact on the
field.
Pharmaceutical cost-effectiveness
Australia was the first country to introduce the requirement that
the cost-effectiveness of new drug therapies be considered explic-
itly before being added to the list eligible for government subsidi-er 1 • 7 January 2008 33
HEALTH CAREsation. Submissions to the Pharmaceutical Benefits Advisory
Committee (PBAC), prepared by the manufacturer, are required to
provide evidence of the drug’s safety, effectiveness and cost-
effectiveness, and are extensively reviewed by an independent
advisory committee assisted by a team of independent evalua-
tors.14 The impetus for the new policy was the recognised need to
determine whether the health gain delivered by a new expensive
pharmaceutical justified its addition to the PBS. This regulatory
requirement has provided the impetus for the development of
pharmacoeconomics capacity within academic units in universi-
ties, within pharmaceutical companies and independent consul-
tancies, and within government. Implementing the policy has
required the development of guidelines for consistent methods
and standardised costs, as well as the development of the human
expertise and capacity to review submitted evidence. The require-
ment for including a cost-effectiveness analysis was a development
of an existing policy mechanism — the PBAC consideration of
safety and effectiveness. It drew on well established methods
accepted internationally, and a small but significant research
capacity in Australia (there were 33 published economic evalua-
tions in the period 1978–1993).15
Workforce planning
Workforce planning is another area where research evidence is
potentially relevant, as the challenge is to ensure adequacy of an
appropriately trained workforce without major undersupply or
oversupply.16 A national structure to undertake health workforce
planning has been in place since 1995, initially covering the
medical workforce, and then extended to nursing and allied health
professions. In spite of this, Australia is facing severe shortages of
trained nurses, doctors in primary care and some medical special-
ties, and professionals in some allied health fields. Workforce
research has also been initiated by various inquiries, as well as the
national workforce planning agencies. Traditional workforce plan-
ning approaches rely on simple projections of demand and supply;
government-led planning which emphasises cooperation of the
various stakeholders cannot readily encompass more innovative
approaches to increasing flexibility and productivity.17 Yet, in this
important area of research, with notable exceptions,18 there has
been little independent or investigator-initiated research in Aus-
tralia.
Underpinning effective health services reform
So, what lessons can we draw from these experiences? One factor
that may have influenced the outcomes is the time frame over
which they were expected to influence policy. In the case of
casemix, Australia made a sustained investment over 5 years
through the Australian Health Care Agreements before expecting it
to have a major impact on policy. This was important, as it allowed
the development of trust and confidence in the system by clini-
cians and policymakers. It was also supported by significant
investment in dissemination of the methods used, developments in
research,  and how casemix was being applied through the
Australian Government’s sponsorship of a series of casemix confer-
ences over several years.
Similarly, the use of economic evaluation by the PBAC was
preceded by widespread consultation with industry, the develop-
ment of briefing and technical papers, and a substantial lead-in
trial period in which the guidelines and processes were developed
before economic evaluation was made mandatory. This took
several years. By contrast, the coordinated care trials were
designed, implemented, undertaken and evaluated all over a
relatively short period that was unlikely to lead to the same level of
confidence in their operation or their outcomes.
Workforce planning has been a policy issue over the past
decade, but, unlike PBAC economic evaluation and casemix
funding, there seems to have been little interest or capacity within
the research community to study workforce issues, although there
have been numerous reports commissioned by the planning
agencies and other inquiries. Unlike the other three case studies, it
has not been clear how workforce research would impact on
current decision-making or funding mechanisms.
These examples reveal three preconditions that are necessary for
health services research to have an impact on policy. Political will
is important; this means both a receptiveness to new ideas and the
readiness to change the status quo. This must be combined with an
appropriate and sustained level of investment over time, and a
time frame that allows for the development of rigour in the
research and confidence from policymakers and players in the
health system. The third and critical precondition that is evident
across the success stories is sufficient capacity among independent
academic researchers to provide the evidence base that supports
and informs the policy initiatives of government.
The need for research capacity
Why has the health services research sector in Australia not been
better developed, given the recommendations made in the various
reviews of research funding, and the international recognition
which Australian health and medical research has achieved? We
suggest that there are a number of reasons.
First, the disappearance of specific funding for investigator-
initiated health services research projects and the shift within
NMHRC to a stronger focus on funding around specific diseases
and body systems has ensured that many health services research-
ers are discouraged from applying. At the same time, there is
growing demand from government departments, other funders of
health care, and provider bodies for contract research, which, as a
result of both limited funding and confidentiality provisions, is less
frequently published.
Second, public health developments supported by the Public
Health Education and Research Program have emphasised preven-
tion, health promotion, and the social determinants of disease;
these initiatives have generally overlooked health services research.
At the same time, university budgets have been contracting, and
this has limited the expansion of emerging fields and new
continuing appointments. As a result, there are fewer opportuni-
ties for an academic career, so fewer health services researchers are
engaged in teaching, leading to fewer students being attracted to
health services research.
Third, health services researchers have been spread through
different academic units, private firms, and small independent
consultancies, while government health department restructures
have generally limited their investment in these skills, preferring to
outsource these functions. This has hindered the development of
critical mass. These problems can only be overcome through a
comprehensive strategy of capacity building that invests in centres
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